Introduction
============

The incidence and prevalence of childhood-onset inflammatory bowel disease (IBD) has risen rapidly over the past two decades ([@bib1]). While previously considered rare in children, IBD has emerged as a global disease in developed and developing nations ([@bib2], [@bib3]). The increasingly early onset of Crohn's disease (CD) and ulcerative colitis (UC) raises important questions regarding the role of early-life factors in the pathogenesis of IBD ([@bib4]). It also represents a significant burden to health care systems ([@bib5]), because the treatment of childhood-onset IBD is more expensive in the long-term ([@bib6]).

Canadian health administrative data represent an unprecedented opportunity to assess the trends in epidemiology and health services utilization of children with IBD. Each Canadian province has independent single-payer health systems, so all legal residents of each province are included within health administrative data. Independently, the trends of pediatric IBD have been described in individual Canadian provinces ([@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12]). However, application of the same case identification algorithm in different jurisdictions without additional validation can result in misclassification bias ([@bib13]). Even though the health administrative data from each province are similar in database population and data structure, research using these data has revealed differences in trends. For example, studies from Ontario have consistently reported increasing incidence in children and teenagers ([@bib7], [@bib8], [@bib9]), with less pronounced increased incidence in adults ([@bib9]). However, research from Quebec ([@bib12]) and Nova Scotia ([@bib11]) has demonstrated stable incidence in children and decreased incidence in adults. These disparities may be due to differences in methodology ([@bib13]), or due to true variation. In addition, single-province studies may not be powered to demonstrate trends in age groups where IBD is rare, such as those with disease onset prior to the age of 10 years.

The Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC) was formed to provide national-level information using distributed network analysis of multiple Canadian provincial health administrative data, reducing heterogeneity of methods and improving power for smaller populations or uncommon outcomes. The aim of this study was to determine trends in incidence and prevalence of childhood-onset IBD in Canada to determine the burden of IBD in Canadian children.

Methods
=======

Study design and setting
------------------------

This study was approved by the research ethics boards of the Children's Hospital of Eastern Ontario, the Ottawa Hospital, University of Manitoba, Dalhousie University, Conjoint Health Research Ethics Board of the University of Calgary, and the Montreal Jewish General Hospital. In addition, this study was reviewed for privacy concerns by Manitoba Health's Health Information Privacy Committee, the Privacy Officer of the Institute for Clinical Evaluative Sciences (ICES), and the Comission d'acces a l'information du Quebec (CAI). We conducted a retrospective cohort study using the provincial health administrative and population databases from five Canadian provinces: Alberta, Manitoba, Nova Scotia, Ontario, and Quebec. These databases contain records of all legal residents of each province, representing a source population of 26,530,074 people, 79.2% of the Canadian population ([@bib14]).

CanGIEC conducted a distributed network analysis in which the same methodology was applied to each Canadian province's health administrative data to produce standardized estimates of incidence and prevalence in each province. In addition, we determined trends over time by age group: overall (6 months to 15.9 years (y) at diagnosis), and in sub-groups: 6 months to 4y, 5--9y, 10--13y, and 14--15.9y at diagnosis or at the time of the point prevalence estimate. Standardized estimates and trends were then combined by meta-analysis using random-effects models analysis to account for heterogeneity. This method has been used previously to conduct observational pharmaco-epidemiology research in Canada and the United Kingdom ([@bib15]).

Population
----------

To create the cohort, we identified all children \<16y at the time of IBD diagnosis in each province. For incident cases, we excluded people with discontinuous health care coverage within the province, such as those who left a province and then returned. Incident cases diagnosed \<6 months old were also excluded due to the risk of misclassification with allergic or other non-IBD causes of enterocolitis. We used validated algorithms to identify persons with IBD for the provinces of Alberta, Manitoba, and Ontario ([@bib7], [@bib16], [@bib17]). These algorithms (see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}) online consisted of combinations of outpatient, hospitalization and procedural codes to accurately distinguish IBD cases from the rest of the population, and have all been validated as the most accurate identification method for the province in which they were applied. The Ontario algorithm was validated and found to be accurate in a population of children with and without IBD from academic and community practices, treated by pediatric gastroenterologists, adult gastroenterologists, and primary care providers ([@bib7]). The Manitoba algorithm was also validated using a random sample chart review from across the province. Although most pediatric patients with IBD were treated in a single-academic center in Winnipeg, the algorithm identified 95% of those patients ([@bib17]). The Alberta algorithm was validated using a reference standard derived from endoscopy reports from the Calgary Health Region and Capital Health Region and included both academic and community practices ([@bib16]). Of note, Quebec cases were identified using a modified version of the Alberta algorithm ([@bib12]), and Nova Scotia cases were identified using the Ontario pediatric algorithm ([@bib7]). To ensure that the lack of validated algorithms in Quebec and Nova Scotia had not altered study conclusions, we conducted a sensitivity analysis without these provinces included.

The date of diagnosis was defined as the date of the first health care contact (either outpatient or hospitalization) within the identification algorithm with associated International Classification of Disease (ICD), ninth-revision (ICD-9) or ICD, tenth revision (ICD-10) for Crohn's disease (CD) or ulcerative colitis (UC): 555.x, 556.x, K50.x, or K51.x. For the incident estimates in all provinces, we applied validated look-back and look-forward qualification periods. The 3-year look-back period has been demonstrated to successfully differentiate incident from prevalent cases in 95% of Ontario children ([@bib7]). A look-back period was not applied in cases where full administrative data was available from birth. In order to qualify as an IBD case, we allowed for the combination of codes to occur within a 3-year interval, which has also been validated as adequate in Ontario children ([@bib7]). Using these look-back and qualification periods, we created study cohorts of incidence and prevalence of childhood IBD from 1999--2010 in Manitoba and Ontario, 1999--2008 for Alberta and Quebec, and 2000--2008 for Nova Scotia. Complete details on data holdings and data availability for this study are presented in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

In children with IBD, validated algorithms were used to classify them as CD, UC, or IBD type unclassifiable (i.e., cases for whom the algorithm could not distinguish CD or UC classification; see [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Disease classification was provided for both the initial diagnosis (grouping of diagnostic codes associated with health care contacts immediately after the date of diagnosis) and latest diagnosis (most recent grouping of health care contacts available for each case). For the purposes of incidence and prevalence estimates, the latest diagnosis was used to reflect the treating physicians' best assessment of disease classification at the end of the study period. Therefore, if a subject's diagnosis changed from UC to CD, they were counted as CD for the incidence and prevalence estimates and for the calculation of time trends.

Data sources
------------

Health administrative data from all provinces consisted of outpatient physician billing records, and hospitalization records. The databases used to identify cases were described in detail in the studies describing validation of the identification algorithms ([@bib7], [@bib16], [@bib17]). In the case of all five provinces, a record of the full IBD population was available to investigators for analysis. In Ontario and Nova Scotia, the full non-IBD population of the province was available to investigators. However, in Alberta, Manitoba, and Quebec general population estimates from the 2001 and 2006 Canadian censuses were used to determine the denominator of incidence and prevalence rates, and to calculate inter-censal population estimates.

Statistical analysis
--------------------

Descriptive statistics were reported as medians with interquartile range (IQR), or proportions where appropriate. Sex- and age-standardized annual prevalence and incidence per 100,000 population were determined for each province for the fiscal years (1 April to 31 March) in which data was available, with corresponding 95% confidence intervals (CI) based on Gamma distribution ([@bib18]). Yearly and overall rates for the age groups (6 months to 4y, 5--9.9y, 10--13.9y, 14--15.9y) were standardized by sex only, with standard populations consisting of at-risk people within the appropriate age group. Trends in incidence over time were reported as an annual percentage change (APC) over the study period by exponentiating the beta coefficient of the sex-adjusted Poisson regression and subtracting it by one (exp(β)-1). This Poisson model was also used to assess statistical significance in trends in incidence over time, stratified by age category with age-appropriate denominator populations. An APC is statistically significant when its 95% CI does not cross zero. Analyses were conducted using SAS v9.4 (SAS Institute Inc., Cary, NC, USA).

Meta-analysis using random-effects models was used to produce national estimates of incidence and prevalence. Incidence and prevalence estimates with 95% CIs were reported for each year, and for the overall study period. We assessed trends in incidence and prevalence over time, stratified by age groups, by meta-analyzing the APC for each province using random-effects models. Only standardized estimates were included in meta-analyses ([@bib19]). Heterogeneity was calculated using the *I*^2^ statistic and Cochrane *χ*^2^ test (*Q*-test), which describe the percentage of total variation across incidence estimates due to heterogeneity rather than chance. We conducted a sensitivity analysis to determine APC in incidence and prevalence excluding provinces without a validated algorithm (Quebec and Nova Scotia). Meta-analyses were conducted with STATA statistical software version 11 (STATA Corp, College Station, TX, USA).

Results
=======

Descriptive characteristics
---------------------------

A total of 5,214 incident cases and 6,554 prevalent cases were included in the study population. The study cohorts are described in [Table 1](#tbl1){ref-type="table"}. For the incidence cohort, the characteristics of the populations in each province were similar. One exception was the greater predominance of CD in Quebec compared to other provinces for initial diagnosis (86.4 vs. 57.7%). Similar results were seen for latest diagnosis (88.5 vs. 59.1%) The median age at diagnosis (for overall cohort: 12.3y, IQR 10.5--14.1) and sex distribution (females 43.3%) was not significantly different between provinces. The sex distribution was not significantly different between age groups, with a male majority present in all pediatric age groups ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Incidence
---------

For the full study period, the overall standardized incidence for all provinces was 9.7 (95% CI 9.1--10.2) per 100,000. The incidence by province is demonstrated in [Table 2](#tbl2){ref-type="table"} and [Figure 1a](#fig1){ref-type="fig"}. The incidence of IBD in all years was lowest for Manitoba (7.2 per 100,000) and highest in Nova Scotia (15.2 per 100,000), with significant heterogeneity amongst provinces (*I*^2^ 76.3%, *P*\<0.001). Similar variation across provinces was present for CD (overall incidence 6.5 per 100,000) and UC (overall incidence 2.4 per 100,000). For CD, both Nova Scotia (9.3 per 100,000) and Quebec (8.8 per 100,000) had higher incidence compared to other provinces. Quebec had a lower incidence of UC compared to other provinces (1.0 per 100,000).

The incidence of IBD over the study period is demonstrated in [Figure 2](#fig2){ref-type="fig"}. Overall incidence per 100,000 children changed from 7.9 (95% CI 6.4 to 9.4) in 1999 to 10.6 (95% CI 8.5 to 12.6) in 2008, the final year that all provinces could contribute data. In 2010, when only Ontario and Manitoba could provide data, the combined incidence was 9.0 (95% CI 4.4 to 13.5) per 100,000. Change in incidence over time is demonstrated in [Figure 3](#fig3){ref-type="fig"}, with graphical representation on a map in [Figure 4a](#fig4){ref-type="fig"}. For children \<16y, the incidence increased over time in Ontario (APC +5.8%, 95% CI +4.6 to +7.0%) and Quebec (APC +2.8% 95% CI +0.9 to +4.7%). Incidence did not change over time in Alberta (APC +1.5%, 95% CI −1.2 to +4.2%), Manitoba (APC −1.4%, 95% CI −5.2 to +2.4%), or Nova Scotia (APC −0.8%, 95% CI −5.8 to +4.2%). Overall, the combined incidence rate was stable (APC +2.1% 95% CI −0.06 to +4.8%). Significant heterogeneity was observed between provinces in APCs over time (*I*^2^ 84.3%, *P*\<0.001). Incidence rates were also stable over time when IBD was stratified into CD (APC +1.7% 95% CI −1.0 to +4.4%) and UC (APC +1.7% −3.8% to +7.1%). The only age group with statistically significant increased incidence was children 6 month to 5y (APC +7.2% 95% CI +2.8 to 11.6%). In this youngest group, incidence did not rise significantly when stratified by CD (APC +3.2% 95% CI −3.2 to +9.7%) and UC (APC +5.5% 95% CI −0.3% to +11.4%). Of note, significant heterogeneity was not present amongst provinces for this age group (IBD: *I*^2^ 9.5%, *P*=0.35; CD: *I*^2^ 0.0%, *P*=0.84; UC: *I*^2^ 0.0%, *P*=0.50). Due to the rarity of cases of children \<5y, the rate change models did not converge for Manitoba in calculation of IBD trends, nor for Manitoba and Nova Scotia in calculation of CD and UC trends.

Results of the sensitivity analysis excluding Nova Scotia and Quebec are presented in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. Excluding provinces without validated identification algorithms did not significantly alter APC of incidence.

Prevalence
----------

Based on meta-analysis, the standardized period prevalence for all provinces was 38.2 (95% CI 35.8 to 40.7) per 100,000 children. The prevalence by province is demonstrated in [Table 2](#tbl2){ref-type="table"} and [Figure 1b](#fig1){ref-type="fig"}. In 2008, the final year in which all provinces reported data, the national point prevalence was 46.2 (95% CI 34.6 to 57.8) per 100,000, significantly increased from the prevalence in 2000 of 33.2 (95% CI 26.6 to 39.8) per 100,000. Overall, the prevalence for CD was 25.5 (95% CI 22.8 to 28.1) per 100,000. For UC, prevalence was 10.7 (95% CI 9.8 to 11.6) per 100,000. [Figure 5](#fig5){ref-type="fig"} demonstrates prevalence by province between 1999 and 2008. Time trends analysis demonstrated statistically significantly increased prevalence in all age groups, except adolescents aged 14--15.9y ([Figure 6](#fig6){ref-type="fig"}). Overall, IBD prevalence increased by 4.6% (95% CI 3.7 to 5.4%) per year, CD prevalence increased by 3.9% (95% CI 1.9 to 5.9%) per year, and UC prevalence increased by 4.4% (95% CI 1.8 to 6.9%) per year ([Figure 4b](#fig4){ref-type="fig"}). Results of the sensitivity analysis excluding Nova Scotia and Quebec are presented in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}. Excluding provinces without validated identification algorithms did not significantly alter APC of prevalence.

Discussion
==========

Using a distributed network methodology applied to five Canadian population-based health administrative databases, we confirmed that Canada has amongst the highest incidence and prevalence of childhood-onset IBD in the world. As previously reported, the predominant form of pediatric-onset IBD is CD, with more boys than girls affected. The incidence of childhood-onset IBD was stable during the first decade of the twenty-first century, with the exception of rising incidence among children diagnosed under the age of 5y. Finally, we noted significant heterogeneity in both incidence and trends over time amongst provinces despite use of standardized analysis, indicating significant regional variation. Extrapolating our results to the entire country, we estimate that approximately 600--650 children are diagnosed with IBD every year, and 2,695 children under 16y were living with IBD in Canada in 2008.

The high incidence and prevalence of pediatric IBD in Canada has been demonstrated in previous single-province studies ([@bib9], [@bib12], [@bib20]). In our study, the incidence of IBD in children was amongst the highest in the world which is consistent with the only previous multi-province Canadian study ([@bib21]). A previous systematic review which included studies published before 2010 demonstrated that only Norway had similar incidence, 10.6 per 100,000 children \<16y ([@bib22]). More recently, a study from Stockholm County, Sweden reported an incidence of 12.8 per 100,000 in children \<16y between 2002--2007, significantly increased from previous reports from the same region ([@bib23]). By contrast, incidence estimates from other regions of Europe and the United States were significantly lower ([@bib1]). The reasons for the higher rates in children from Canada and Northern Europe are not known. Lack of sunlight exposure and high rates of vitamin D deficiency, antibiotic use, diet, and migration patterns have been hypothesized as contributors ([@bib4], [@bib24]). The interaction between environmental risk factors, the intestinal microbiome, and genetic predisposition are important areas under investigation. This trend of increased incidence in the northern latitude has also been demonstrated in the United States ([@bib25]). Even amongst northern states, incidence may be increasing. A recent population-based study from Rhode Island demonstrated a much higher incidence of IBD in children and adults ([@bib26]) compared with older estimates from Wisconsin ([@bib27]) and Minnesota ([@bib28]). It remains to be seen whether American states at northern latitudes will develop a similarly high incidence of pediatric IBD noted in Canada over the past two decades.

The incidence of pediatric IBD was stable during the study period, with the exception of incidence in children under 5 years old. The rise in the incidence of very early onset IBD (VEO-IBD) ([@bib29]) in our study population was consistent across all provinces as evidence by the lack of statistical heterogeneity between provinces. The rapid increase in VEO-IBD was previously noted in Ontario ([@bib8]). This multi-province study demonstrated that incidence was rising by \~7% per year in that age group, with little heterogeneity amongst provinces. This finding may also explain the observation of increased prevalence of children \<16y living with IBD, since these VEO-IBD cases would remain in the cohort for longer. However, the reason for the increased incidence of VEO-IBD cases in Canada is unexplained. While IBD diagnosed in children \<2y is more likely due to monogenic factors ([@bib30]), this represented a very small proportion of our VEO-IBD cohort. Therefore, most patients with a diagnosis \<6y were not likely to have the monogenic forms of IBD, and early-life environmental factors may have played a role in the observed increased incidence ([@bib4]). The association between early-life environmental factors and childhood-onset IBD was particularly noted in studies demonstrating increased risk due to early-life antibiotic ([@bib31]) and air pollution exposure ([@bib32]). However, changes in health services factors may also have resulted in increased recognition in young children. Whereas all studies relying on administrative database are subject to misclassification errors on the study population, this bias is less likely in children under the age of 5 years because a previous validation study showed that only 1% of children diagnosed \<6y did not have any health services contacts with associated IBD diagnoses at the end of a mean 9y follow-up period ([@bib8]). This means that most children initially labeled IBD continued to be treated as IBD years later.

There was significant heterogeneity in estimates of incidence, prevalence, and trends over time for those diagnosed above 5y old, indicating variation between provinces. In particular, we noted that Nova Scotia demonstrated significantly higher incidence and prevalence of IBD compared with other provinces. In addition, Quebec demonstrated a much greater proportion of IBD patients being classified as having CD compared with UC. Both of these findings were demonstrated in other adult-focused cohort studies, and remain unexplained ([@bib12], [@bib21]). Different genetic backgrounds may play a role. Quebec is primarily comprised of a unique French Canadian (Quebecois) population with a distinct phenotype ([@bib33]). Nova Scotia is comprised of 31% of people of Scottish origin and 28% of people from other British Isles (compared to 15 and 20%, respectively, in all Canadians) ([@bib34]), and Scotland has been noted to have a higher incidence of pediatric IBD than the rest of the United Kingdom ([@bib35]). Finally, Ontario and Quebec have larger immigrant populations than other provinces, and Manitoba has a higher First Nations population than other provinces. Immigrants and First Nations people have been demonstrated to have lower rates of IBD than other Canadians ([@bib36], [@bib37], [@bib38]). Finally, the differences in incidence observed amongst provinces may be related to access to health services. If families from Nova Scotia are more likely to seek medical attention for their children, this would explain the higher incidence observed. Of note, pediatric asthma prevalence was also reported to be higher in Nova Scotia than other provinces ([@bib39]). Future research will examine the issue of access and variation of care of children with IBD in Canada.

The rising incidence of VEO-IBD, and particularly in children under 5 years has important clinical implications. Children with onset of disease at younger ages have been demonstrated to have lower rates of hospitalization, emergency department utilization and surgical resection ([@bib8], [@bib40], [@bib41], [@bib42]). However, these patients will live longer with the disease and research regarding long-term outcomes is lacking. In addition, young children present more frequently with isolated colonic disease, with a change to a more ileo-colonic phenotype in children presenting between 6--9 years old ([@bib40], [@bib42]). Therefore, it is much more difficult to determine IBD sub-type in children under 6 years presenting with colitis, which may impact medication choice, and the decision on whether to proceed to colectomy in patients failing medical management. Finally, the psycho-social impact on the family of caring for a young child with a chronic illness is significant. This may be reflected in the need for age-appropriate educational material, decisions regarding medical or dietary therapy, when to proceed to surgery, frequent school absences for the child, or parental absences from work. These issues may be best addressed in centers offering multi-disciplinary care such as support from a psychologist, social worker, dietitian, and specialized nurse. In light of these unique challenges in very young children with IBD, we recommend that these patients be treated by specialized pediatricians with expertise in multi-disciplinary IBD care. In addition, we would suggest that the Paris classification of pediatric IBD be modified to sub-categorized VEO-IBD (diagnosis under 10-years old) between those diagnosed \<6 years and those diagnosed between 6 and 10 years. This modification would acknowledge the rising incidence and the uniqueness of this cohort, and encourage further research into etiology, natural history and therapeutic options in young children.

Limitations
-----------

Misclassification bias can always affect research using routinely collected health data ([@bib43]), and the heterogeneity observed amongst provincial results may have been due to the use of different algorithms to identify IBD patients in each province. We used the most accurate identification and classification algorithms for each specific province to reduce the risk of misclassification error, and the algorithms used were validated in the provinces to which they were applied (for Alberta, Manitoba, and Ontario). In contrast, Nova Scotia and Quebec applied non-validated coding algorithms and were the provinces with the most inconsistent findings. A sensitivity analysis that included only provinces that identified patients with locally validated algorithms did not demonstrate different findings. Nonetheless, no administrative data algorithm is completely accurate, and differential accuracies may have resulted in the appearance of heterogeneity. Future work will continue to develop and validate algorithms to identify patients with IBD, and to identify the causes of the variation seen across Canadian provinces.

This study was also limited by the time periods of data availability, and particularly by the requirement for look-back and look-forward periods to differentiate incident from prevalent cases. While use of these validated periods ensured accurate estimates of incidence, we were unable to determine trends in incidence prior to or after the study period. In addition, our analysis was able to determine overall ecological trends in IBD epidemiology, but not the reasons for the observed changes. Future research should determine whether changing environmental risk factors, new gene-environment interactions and/or alterations to the health system resulted in the changing rates.

Conclusions
===========

In summary, we have demonstrated that Canada has amongst the highest rates of childhood-onset IBD in the world. While the incidence of IBD has stabilized in children over the age of 5 years, the incidence is rising rapidly in children under 5 years old. These findings have important implications on the children, their families, and the health care system, because these children will live longer with the disease, have a more extensive disease phenotype, and result in higher direct costs for IBD care compared with adults ([@bib6], [@bib44]). In addition, the increasingly early age of onset implies early-life environmental triggers in at-risk patients. Since young children are exposed to fewer environmental triggers in the course of their short lives, future research should focus on identification of triggers in children with IBD, understanding the biology behind changes resulting in disease, and intervention to prevent the occurrence of IBD in this vulnerable age group.
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================
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![(**a**) Incidence of IBD (1999--2010) and (**b**) prevalence of IBD in the final year of available data in each province of Canada.](ajg201797f1){#fig1}

![Annual standardized incidence (per 100,000 population) of (**a**) IBD, (**b**) Crohn's disease, and (**c**) ulcerative colitis in Canada (1999--2010).](ajg201797f2){#fig2}

![Annual percentage change in incidence of (**a**) IBD, (**b**) CD, and (**c**) UC by age group. Meta-analysis was conducted to combine provincial estimates. *I*^2^ was calculated to determine heterogeneity in provincial results.](ajg201797f3){#fig3}

![Annual percentage change in (**a**) incidence and (**b**) prevalence represented on a map of Canada. \**P*\<0.05 for increased incidence over time; ^\#^*P*\<0.05 for decreased incidence over time.](ajg201797f4){#fig4}

![Annual standardized prevalence (per 100,000 population) of (**a**) IBD, (**b**) Crohn's disease, and (**c**) ulcerative colitis in Canada on July 1 of the final year of the provincial cohort (2008 for Nova Scotia and Quebec, 2010 for Alberta, Manitoba, and Ontario).](ajg201797f5){#fig5}

![Annual percentage change in prevalence of IBD by age group. Meta-analysis was conducted to combine provincial estimates. *I*^2^ was calculated to determine heterogeneity in provincial results.](ajg201797f6){#fig6}

###### Descriptive characteristics of the study cohort of incident cases of IBD in children \<16 in Canada

                                                                                                                      **Alberta**        **Manitoba**                            **Nova Scotia**     **Ontario**         **Quebec**          **Overall**
  ------------------------------------------------------------------------------------------------------------------- ------------------ --------------------------------------- ------------------- ------------------- ------------------- ----------------------
  *Incidence cohort (diagnosed with IBD, age \<16y, 1999--2010)*                                                                                                                                                                             
   Cases (*n*)                                                                                                        655                221                                     236                 2,656               1,437               5,214
   Median age in years at diagnosis (IQR)                                                                             12.0 (9.0--14.0)   12.8 (10.7--14.6)                       12.0 (10.0--14.0)   12.8 (10.3--14.6)   13.3 (11.0--14.8)   12.64 (11.71--13.56)
   Age at diagnosis                                                                                                                                                                                                                          
    6 months--4.9y                                                                                                    82 (12.5%)         NA[a](#t1-fn2){ref-type="fn"}           13 (5.5%)           136 (5.1%)          34 (2.4%)           265 (5.1%)
    5--9.9y                                                                                                           112 (17.1%)        46 (20.8%)[a](#t1-fn2){ref-type="fn"}   38 (16.1%)          471 (17.7%)         223 (15.5%)         890 (17.1%)
    10--13.9y                                                                                                         245 (37.4%)        102 (46.2%)                             112 (47.5%)         1,144 (43.1%)       595 (41.4%)         2,200 (42.2%)
    14--15.9y                                                                                                         216 (33.0%)        73 (33.0%)                              73 (30.9%)          905 (34.1%)         585 (40.7%)         1,852 (35.5%)
   Sex (F)                                                                                                            298 (45.5%)        101 (45.7%)                             101 (42.8%)         1,125 (42.4%)       628 (43.7%)         2,556 (43.3%)
   Initial diagnosis                                                                                                                                                                                                                         
    CD                                                                                                                396 (60.5%)        131 (59.3%)                             151 (64.0%)         1,497 (56.4%)       1,242 (86.4%)       3,421 (65.6%)
    UC                                                                                                                187 (28.5%)        90 (40.7%)                              70 (29.7%)          926 (34.9%)         159 (11.1%)         1,435 (27.5%)
    IBD type unclassifiable                                                                                           72 (11.0%)         NA                                      15 (6.4%)           233 (8.8%)          36 (2.5%)           358 (6.9%)
   Latest Diagnosis                                                                                                                                                                                                                          
    CD                                                                                                                386 (62.0%)        129 (58.4%)                             149 (63.1%)         1,570 (59.1%)       1,228 (88.5%)       3,462 (67.6%)
    UC                                                                                                                192 (30.8%)        92 (41.6%)                              73 (30.9%)          902 (34.0%)         123 (8.9%)          1,382 (27.0%)
    IBD type unclassifiable                                                                                           45 (7.2%)          NA                                      14 (5.9%)           184 (6.9%)          36 (2.6%)           279 (5.4%)
  *Prevalence cohort (alive and \<16y on 1 July 2010 (Manitoba and Ontario) or 2008 (Alberta, Nova Scotia, Quebec)*                                                                                                                          
   Cases (*n*)                                                                                                        360                67                                      99                  1,025               681                 3,328
   Median age in years at diagnosis (IQR)                                                                             12 (9.0--14.0)     10.7 (8.1--13.3)                        10.0 (7.0--12.0)    13.4 (10.8--14.9)   11.4 (8.3--13.5)    12.1 (11.1--13.1)
   Sex (F)                                                                                                            167 (46.4%)        31 (46.3%)                              43 (43.4%)          431 (42.0%)         278 (40.8%)         1,465 (44.0%)
   Latest diagnosis                                                                                                                                                                                                                          
    CD                                                                                                                188 (53.3%)        42 (62.7%)                              62 (62.6%)          554 (54.0%)         580 (89.5%)         2,360 (70.9%)
    UC                                                                                                                110 (31.2%)        25 (37.3%)                              32 (32.3%)          380 (37.1%)         67 (9.8%)           714 (21.4%)
    IBD type unclassifiable                                                                                           55 (15.6%)         NA                                      5 (5.1%)            91 (8.9%)           19 (2.8%)           190 (5.7%)

CD, Crohn's disease; IBD, inflammatory bowel disease; IQR, interquartile range; UC, ulcerative colitis; y: years.

Due to small cell size, raw count was suppressed. The count for children diagnosed \<10y was combined.

###### Standardized incidence and prevalence over the full study period (1999--2010) based on meta-analysis of annual estimatesContinued

  --------------------------------------------------- ------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ------------------------ ------------------------------------
                                                             **Alberta**                **Manitoba**                 **Nova Scotia**                 **Ontario**                   **Quebec**              **All provinces**      ***I***^**2**^ (***P*** **value)**
                                                             **Alberta**                **Manitoba**                 **Nova Scotia**                 **Ontario**                   **Quebec**              **All provinces**      ***I***^**2**^ (***P*** **value)**
  *Incidence*                                                                                                                                                                                                                    
   IBD                                                                                                                                                                                                                           
    Number of cases                                              655                         221                           236                          2,656                         1,437                      5,214                             
    Incidence per 100,000 (95% CI)                       9.71 (8.81--10.62)           7.22 (6.18--8.26)            15.18 (13.1--17.25)           9.28 (8.22--10.34)            10.26 (9.50--11.02)         9.68 (9.11--10.25)             76.3% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                       3.60 (2.68--4.53)      [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        1.54 (1.11--1.97)        [a](#t2-fn2){ref-type="fn"}     2.06 (1.56--2.55)              60.2% (*P*\<0.001)
     5--9.9y                                              4.88 (3.79--5.98)           3.32 (1.91--4.73)        [a](#t2-fn2){ref-type="fn"}        5.04 (4.12--5.96)             3.70 (3.04--4.37)          4.41 (3.91--4.91)              54.5% (*P*\<0.001)
     10--13.9y                                          13.62 (11.84--15.40)         11.49 (8.88--14.11)          24.67 (18.67--30.67)          14.26 (12.66--15.87)          13.98 (12.64--15.32)        14.13 (13.23--15.04)            50.4% (*P*\<0.001)
     14--15.9y                                          22.31 (18.29--26.32)        15.77 (11.39--20.16)          31.68 (23.44--39.92)          21.88 (19.07--24.69)          28.20 (25.35--31.05)        23.61 (21.72--25.49)            62.9% (*P*\<0.001)
   CD                                                                                                                                                                                                                            
    Number of cases                                              386                         129                           149                          1,570                         1,228                      3,462                             
    Incidence per 100,000 (95% CI)                        5.89 (5.30--6.48)           4.17 (3.36--4.97)            9.34 (7.69--11.00)             5.48 (4.91--6.04)             8.80 (8.15--9.45)          6.47 (5.91--7.04)              85.2% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                       1.62 (0.93--2.32)      [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        0.40 (0.22--0.57)        [a](#t2-fn2){ref-type="fn"}     0.51 (0.32--0.71)               13.9% (*P*=0.28)
     5--9.9y                                              1.94 (1.25--2.63)           2.01 (0.77--3.24)        [a](#t2-fn2){ref-type="fn"}        2.66 (2.15--3.18)             3.07 (2.51--3.62)          2.65 (2.35--2.96)               30.9% (*P*=0.03)
     10--13.9y                                           9.52 (8.01--11.02)           6.60 (4.26--8.93)           16.41 (11.35--21.47)           9.21 (8.06--10.36)           12.21 (11.01--13.37)        10.13 (9.26--11.01)             62.2% (*P*\<0.001)
     14--15.9y                                          14.40 (11.30--17.49)         8.39 (4.87--11.91)            15.98 (9.83--22.12)          12.84 (11.06--14.62)          24.11 (21.67--26.55)        16.11 (14.10--18.11)            79.0% (*P*\<0.001)
   UC                                                                                                                                                                                                                            
    Number of cases                                              192                         92                            73                            902                           123                       1,382                             
    Incidence per 100,000 (95% CI)                        2.67 (2.13--3.21)           2.77 (2.02--3.51)             4.22 (3.03--5.41)             3.11 (2.66--3.56)             0.99 (0.92--1.06)          2.35 (2.09--2.61)              89.6% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                       1.02 (0.41--1.64)      [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        0.81 (0.59--1.03)        [a](#t2-fn2){ref-type="fn"}     0.83 (0.62--1.04)               0.0% (*P*=0.71)
     5--9.9y                                              1.42 (0.80--2.05)           1.99 (0.76--3.23)        [a](#t2-fn2){ref-type="fn"}        1.82 (1.39--2.25)             0.13 (0.09--0.17)          0.54 (0.40--0.68)              75.7% (*P*\<0.001)
     10--13.9y                                            3.13 (2.07--4.19)           4.10 (2.32--5.87)             5.62 (2.87--8.37)             3.98 (3.33--4.62)             1.16 (1.03--1.30)          2.55 (2.18--2.93)              75.2% (*P*\<0.001)
     14--15.9y                                            5.66 (3.92--7.41)           6.73 (3.62--9.85)            8.33 (3.57--13.09)             7.43 (6.21--8.65)             2.89 (2.60--3.19)          4.91 (4.26--5.56)              64.6% (*P*\<0.001)
  *Prevalence*                                                                                                                                                                                                                   
   IBD                                                                                                                                                                                                                           
    Number of cases (in final year of study period)              360                         67                            99                           1,025                          681                       2,228                             
    Prevalence per 100,000 (95% CI)                     44.48 (40.87--48.08)        28.33 (21.95--35.95)          53.79 (49.63--57.95)          31.80 (29.18--34.42)          44.06 (39.00--49.12)        38.25 (35.78--40.73)            96.2% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                      11.15 (9.60--12.69)     [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        2.68 (2.14--3.23)             3.76 (2.89--4.62)          4.45 (3.71--5.19)              82.4% (*P*\<0.001)
     5--9.9y                                            24.85 (20.23--29.48)         8.12 (2.98--17.64)           15.26 (13.05--17.46)       [a](#t2-fn2){ref-type="fn"}      11.02 (10.23--11.80)        14.10 (12.62--15.59)            86.1% (*P*\<0.001)
     10--13.9y                                          65.11 (60.35--69.87)        36.32 (23.02--54.48)          86.13 (76.84--95.42)          49.41 (45.06--53.76)          36.86 (34.61--39.11)        50.63 (47.30--53.97)            89.2% (*P*\<0.001)
     14--15.9y                                         113.71 (105.52--121.90)      104.70 (73.31--144.9)        141.35 (123.98--158.73)       100.79 (94.34--107.21)         59.63 (53.68--65.58)       94.15 (86.77--101.52)            92.7% (*P*\<0.001)
   CD                                                                                                                                                                                                                            
    Number of cases (in final year of study period)              185                         42                            62                            554                           595                       1,435                             
    Prevalence per 100,000 (95% CI)                     26.18 (24.97--27.39)         17.85 (12.87--24.1)          37.85 (34.66--41.05)          17.67 (16.27--19.07)          37.50 (33.19--41.81)        25.47 (22.85--28.09)            98.0% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                       4.30 (3.31--5.30)      [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        0.70 (0.48--0.92)             3.24 (2.49--3.99)          2.23 (1.74--2.72)              83.1% (*P*\<0.001)
     5--9.9y                                             9.56 (8.04--11.08)           2.71 (0.33--9.72)        [a](#t2-fn2){ref-type="fn"}        6.05 (5.34--6.76)             8.76 (8.13--9.40)          7.06 (6.32--7.80)              70.4% (*P*\<0.001)
     10--13.9y                                          40.86 (37.90--43.82)         22.13 (12.1--37.11)          63.81 (55.78--71.84)          28.61 (25.73--31.49)            3 (30.69--34.67)          32.82 (30.70--34.94)            81.3% (*P*\<0.001)
     14--15.9y                                          77.59 (71.74--83.45)        75.64 (49.41--110.8)         102.55 (85.53--119.57)         60.56 (56.30--64.82)          50.75 (45.70--55.80)       60.97 (57.03----64.90)           81.0% (*P*\<0.001)
   UC                                                                                                                                                                                                                            
    Number of cases (in final year of study period)              110                         25                            32                            380                           67                         613                              
    Prevalence per 100,000 (95% CI)                     12.92 (10.86--14.97)         10.47 (6.78--15.43)          13.59 (10.63--16.55)          12.04 (11.04--13.03)            6.22 (5.49--6.95)         10.70 (9.84--11.56)             95.9% (*P*\<0.001)
    Age group                                                                                                                                                                                                                    
     6 months--4.9y                                       2.54 (1.75--3.33)      [a](#t2-fn2){ref-type="fn"}   [a](#t2-fn2){ref-type="fn"}        1.56 (1.27--1.85)             0.70 (0.49--0.90)          1.33 (1.07--1.59)              50.2% (*P*=0.001)
     5--9.9y                                             9.64 (7.71--11.57)          5.42 (1.48--13.83)        [a](#t2-fn2){ref-type="fn"}        7.80 (6.46--9.15)             1.56 (1.38--1.74)          5.31 (4.56--6.06)              92.2% (*P*\<0.001)
     10--13.9y                                          18.54 (14.31--22.77)         14.19 (6.49--26.93)          19.34 (13.34--25.33)          17.54 (16.10--18.99)            3.90 (3.65--4.16)         13.46 (12.06--14.85)            95.0% (*P*\<0.001)
     14--15.9y                                          27.08 (22.82--31.35)        29.03 (13.92--53.41)          30.94 (22.80--39.09)          34.10 (31.92--36.27)            6.97 (6.30--7.64)         24.02 (21.56--26.48)            95.0% (*P*\<0.001)
  --------------------------------------------------- ------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- ------------------------ ------------------------------------

CD, Crohn's disease; CI, confidence intervals; IBD, inflammatory bowel disease; UC, ulcerative colitis; y, years.

Due to small cell size, standardized incidence model did not converge.
